Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Recent studies have shown gender differences in cardiovascular outcomes after left atrial appendage closure (LAAC), highlighting different complication rates and adverse events, particularly in short-term assessments. As a result, there remains a significant knowledge gap on how these differences directly impact the efficacy and safety of LAAC procedures. The aim of this retrospective study was to investigate the clinical outcomes of LAAC in women and men using the Watchman FLX device.
Methods: This retrospective, multicenter study analyzes gender-specific outcomes in 650 patients who underwent LAAC with the Watchman FLX device between March 2019 and May 2022, drawn from the ITALIAN-FLX registry.
Results: The results show comparable rates of all-cause mortality, stroke, transient ischemic attack and major bleeding in men and women 12 months after the procedure. Notably, no significant gender differences were found for periprocedural complications.
Conclusion: In conclusion, this study shows that LAAC with the Watchman FLX device has comparable clinical outcomes between genders at both short-term and long-term follow-up.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321078 | PMC |
| http://dx.doi.org/10.3389/fcvm.2024.1419018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transjugular Access for Left Atrial Appendage Closure.
JACC Case Rep
August 2025
Interventional Cardiology, Tucson Medical Center, Tucson, Arizona, USA; U.S. Heart and Vascular, Tucson, Arizona, USA.
Background: Percutaneous left atrial appendage closure (LAAC) is an established therapy for stroke prevention in atrial fibrillation patients unable to tolerate long-term oral anticoagulation. Transfemoral access is standard, but may be precluded by chronic venous occlusion, severe iliocaval tortuosity, or other anatomical barriers.
Case Summary: We describe 2 patients with paroxysmal atrial fibrillation, elevated thromboembolic risk, and absolute contraindications to anticoagulation who were unsuitable for transfemoral LAAC due to prohibitive femoral venous anatomy.
Intraprocedural Thrombus Formation During Left Atrial Appendage Closure: A Conservative Approach.
JACC Case Rep
August 2025
Department of Cardiology, Southeast Health, Dothan, Alabama, USA.
Background: Left atrial appendage closure with the Watchman FLX Pro device (Boston Scientific) is an alternative to anticoagulation in patients at high bleeding risk with atrial fibrillation. Intraprocedural thrombus formation is rare and poses a unique challenge.
Case Summary: A 57-year-old man with paroxysmal atrial fibrillation and prior intracranial hemorrhage underwent elective left atrial appendage closure.
Percutaneous Removal of Left Atrial Appendage Occlusion Device With a Dedicated Retrieval System.
JACC Case Rep
August 2025
Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, Ohio, USA. Electronic address:
Objective: Successful use of a novel percutaneous retrieval system (ŌNŌ retrieval system, ŌNŌCOR) to remove a significantly dislodged left atrial appendage occlusion device (Watchman FLX, Boston Scientific).
Key Steps: First, a 17-F Bayliss VersaConnect and TruSteer catheter was advanced through a 20-F DrySeal sheath (Gore Medical). Then, the ŌNŌ retrieval system was advanced and positioned against the Watchman FLX device.
Streamlined concomitant pulse field ablation-based pulmonary vein isolation and left atrial appendage occlusion via a single venous access approach: a case report.
Eur Heart J Case Rep
August 2025
Department of Rhythmology, Cardiology and Internal Medicine, Asklepios Klinik Altona, Paul-Ehrlich-Straße 1, Hamburg 22763, Germany.
Background: Pulsed field ablation (PFA) is a novel non-thermal cardiac ablation method utilizing irreversible electroporation which has been introduced especially for treatment of atrial fibrillation (AF) by pulmonary vein isolation (PVI). Interventional left atrial appendage closure (LAAC) is an alternative to oral anticoagulation (OAC) in patients with non-valvular AF and high stroke risk who are ineligible for OAC. A concomitant PVI and LAAC might be beneficial for patients.
View Article and Find Full Text PDFIncidence and Predictors of Persistent Left Atrial Appendage Patency and its Subtypes after Percutaneous Closure: a Pre-Specified Analysis of the SWISS-APERO Trial.
Eur Heart J Cardiovasc Imaging
August 2025
Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland.
Aims: Left atrial appendage (LAA) patency after percutaneous closure is associated with higher thromboembolic risk, especially when detected at later time points after procedure. We aim to investigate the incidence and predictors of persistent LAA patency and its different subtypes at cardiac computed tomography angiography (CCTA) during the first year after LAA closure (LAAC).
Methods: In the SWISS APERO trial, patients undergoing LAAC were randomly assigned (1:1) to Amulet or Watchman/FLX across 8 European centers and received CCTA follow-up at 45 days and 13 months.